MedPath

Bone Loss in Patients With Anorexia Nervosa

Not Applicable
Conditions
Patients With Anorexia Nervosa
Registration Number
NCT01907464
Lead Sponsor
University Hospital, Montpellier
Brief Summary

Nutritional deprivation of adolescent girls with anorexia nervosa (AN) reduces the bone mass acquisition. A better understanding of this process would improve the medical treatment of bone alteration and its long-term consequences.

160 patients (age \< 38 yr) with AN and 160 age-matched controls (CON) will be enrolled in this study. The areal bone mineral density (aBMD) will be determined using dual-X-ray absorptiometry. Calciotropic hormones, bone turnover markers will be concomitantly evaluated.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
320
Inclusion Criteria
  • Informed Consent
  • Health Insurance regimen or benefit from an health insurance regimen
  • Aged from 14 to 38 years old
  • Women
  • No pregnant

Specific inclusion criteria for patient:

Patient suffering from anorexia nervosa defined by criteria of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)

Specific inclusion criteria for controls:

  • Normal menstrual cycles,
  • No lifetime history of eating disorders,
  • BMI between 18 and 25 kg/m²
Exclusion Criteria
  • use of treatments may be modify bone mass (bisphosphonates,...)
  • Disease or treatment may be induce osteoporosis
  • In exclusion period in relation with another study
  • Law protected subject

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Dual-X-ray absorptiometry (DEXA)at Day 0 (time of the inclusion visit)

The primary outcome is to model the bone mass acquisition in young women with anorexia nervosa.

Secondary Outcome Measures
NameTimeMethod
Biological parameters identificationAt day 0 (time of the inclusion visit)

One of the secondary outcome is to identify biological factors associated with bone demineralisation.

clinical parameters identificationAt Day 0 (at time of the the inclusion visit)

One of the secondary outcome is to identify the clinical factors associated with bone demineralisation.

Trial Locations

Locations (1)

CHU de Montpellier - Département d'Endocrinologie Diabète

🇫🇷

Montpellier, France

CHU de Montpellier - Département d'Endocrinologie Diabète
🇫🇷Montpellier, France
Laurent LM MAIMOUN, PhD
Contact
+33 4 67 33 79 99
l-maimoun@chu-montpellier.fr
Patrick PL LEFEBVRE, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.